MedTrace Logo

Anticoagulation in Chronic Hemodialysis Patients Versus Hemodialyzer Fiber Patency, Bleedings and Quality of Life

NCT05365542 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2023-05-06

No results posted yet for this study

Summary

Stable chronic hemodialysis patients are included in this observational study. After a midweek dialysis (test moment 1), the hemodialyzer is dried and scanned in a micro Computed Tomography scanner to quantify the number of patent fibers. All dialysis parameters are collected as well as the anticoagulation dose. During the same session, patients are asked about their bleeding and quality of life status. Four (test moment 2) respectively eight weeks later (test moment 3), patients are asked again for their bleeding and quality of life status using validated questionnaires.

Conditions

  • Blood Coagulation

Interventions

OTHER

Hemodialyzer scanning

After the hemodialysis session, the used dialyzer is rinsed and dried before scanning in a Micro Computed Tomography scanner. From cross-sectional images, the number of patent fibers is quantified.

OTHER

Bleeding Questionnaires

The ISTH Bleeding Assessment Tool and the HASBLED questionnaires are asked

OTHER

Quality of life questionnaire

The EQ5D questionnaire is asked.

OTHER

Visual inspection of the limbs

Visual inspection is done of the patient's limbs in order to quantify bruising.

Sponsors & Collaborators

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Wim Van Biesen · UZ Gent

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-27
Primary Completion
2022-07-10
Completion
2022-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05365542 on ClinicalTrials.gov